Synaptic molecular and neurophysiological markers are independent predictors of progression in Alzheimer’s disease

Manuscript Number: 

20-1234R3

Author(s): 
Nicholas J. Ashton, Kaj Blennow, Kina Höglund, Vesna Jelić, Thomas Koenig, Ingemar Kåreholt, Per Nilsson, Una Smailovic, Bengt Winblad, Henrik Zetterberg

Disclosures

Nicholas J. Ashton

  • Nothing to Disclose

Kaj Blennow

  • Patents/Royalties
    KB has served as a consultant, at advisory boards, or at data monitoring committees for Abcam, Axon, Biogen, JOMDD/Shimadzu. Julius Clinical, Lilly, MagQu, Novartis, Prothena, Roche Diagnostics, and Siemens Healthineers, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program (all outside the work presented in this paper.

Kina Höglund

  • Nothing to Disclose

Vesna Jelić

  • Consulting Fees:
    BIOGEN advisory board, expert-participation on one occasion.

Ingemar Kåreholt

  • Nothing to Disclose

Thomas Koenig

  • Nothing to Disclose

Per Nilsson

  • Nothing to Disclose

Una Smailovic

  • Nothing to Disclose

Bengt Winblad

  • Consulting Fees:
    I am member of SAB for: Axon Neuroscience, Alzinova, Biogen.

Henrik Zetterberg

  • Consulting Fees:
    HZ has served at scientific advisory boards for Denali, Roche Diagnostics, Wave, Samumed, Siemens Healthineers, Pinteon Therapeutics and CogRx.
    Equity:
    HZ is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program.
    Lecture Fees:
    HZ has given lectures in symposia sponsored by Fujirebio, Alzecure and Biogen.